指南与共识浆细胞疾病

基于二代测序对新诊断多发性骨髓瘤患者高危基因组共识定义的验证

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.
指南 / 共识 · Blood · 2026-01-01

该研究对2019至2024年间6528例新诊断多发性骨髓瘤(NDMM)患者和1583例首次复发患者进行二代测序 panel 检测,验证国际骨髓瘤学会(IMS)/国际骨髓瘤工作组(IMWG)提出的高危基因组共识模型。22.4%新诊断患者和36.7%首次复发患者按共识基因组分期被归为高危;中位随访35个月,高危NDMM患者中位无进展生存期(PFS)为30个月,标危患者为51个月(P<.0001)。del(17p)、TP53突变、双等位del(1p32)或中危细胞遗传学组合均显著缩短PFS,且累积多个标准者预后更差。

要点

  • IMS/IMWG高危基因组共识定义在6528例NDMM和1583例首次复发患者中得到验证。
  • 高危NDMM中位PFS 30个月 vs 标危51个月(P<.0001),中位随访35个月。
  • del(17p)、TP53突变、双等位del(1p32)或中危细胞遗传学组合均显著降低PFS。

核心结论

  • 该研究在2019年起诊断的大规模患者队列中验证了IMS/IMWG高危骨髓瘤基因组定义。
  • 按共识基因组分期,22.4%新诊断患者和36.7%首次复发患者被归为高危。

研究设计与样本

  • 研究对2019至2024年间6528例新诊断多发性骨髓瘤患者和1583例首次复发患者的样本进行二代测序 panel 检测。
  • 2695例新诊断患者有可用临床数据,中位随访35个月。

主要发现

  • 高危NDMM患者中位PFS为30个月,标危患者为51个月(P<.0001)。
  • 修订版国际分期系统(R-ISS)的高危细胞遗传学标准无法基于IMS/IMWG基因组亚组区分高危与标危患者。
  • 单独分析各标准时,del(17p)、TP53突变、双等位del(1p32)或中危细胞遗传学组合(gain 1q、del(1p32)、t(4;14)、t(14;16)、t(14;20))与标危患者相比均显著缩短PFS。
  • 累积多个高危标准的患者预后更差。
  • 在按基因组定义归为标危且肌酐正常的患者中,高β2-微球蛋白水平者的中位PFS与β2-微球蛋白正常者无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prognostic heterogeneity of multiple myeloma is mainly driven by the genomic features of myeloma cells. The International Myeloma Society (IMS)/International Myeloma Working Group (IMWG) recently proposed a high-risk (HR) genomic model to have a consensus definition of genomic risk. We performed next-generation sequencing in the form of a panel on samples from 6528 patients with newly diagnosed multiple myeloma (NDMM) and 1583 patients at first relapse between 2019 and 2024. We observed that 22.4% of patients at diagnosis and 36.7% of patients at first relapse were classified as high risk according to the Consensus Genomic Staging. Clinical data were available for 2695 patients at diagnosis. After a median follow-up of 35 months, the median progression-free survival (PFS) was 30 months for patients with HR NDMM and 51 months for standard-risk (SR) patients (P< .0001). The HR cytogenetic criteria from the Revised- International Staging System score were not able to differentiate between HR and SR patients based on the IMS/IMWG genomic subgroups. Looking at each criterion independently, we found that the presence of del(17p), TP53 mutation, biallelic del(1p32), or the combination of intermediate-risk cytogenetics (gain 1q, del(1p32), t(4;14), t(14;16), t(14;20)) significantly reduced the PFS when compared with SR patients. Moreover, patients with several cumulating criteria had an even worse prognosis. Among SR patients, classified according to the genomic definition with normal creatinine, the median PFS for those with high β2-microglobulin was not significantly different from that of patients with normal β2-microglobulin level. This study validated the IMS/IMWG genomic definition of HR myeloma in a large cohort of patients diagnosed from 2019 onwards.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Schavgoulidze A, Perrot A, Leleu X, et al. High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing. Blood. 2026. PMID: 40991836. doi:10.1182/blood.2025029999

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。